Decision: Favourable
Study Title:
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
NREC Code:
22-NREC-CT-161
Decision:
Favourable
Meeting Date:
19/10/2022
Study Type:
CT Application
Principal Investigator:
Dr Katherine O'Reilly
PI Institution:
Mater Misericordiae University Hospital
Sponsor:
Horizon Therapeutics Ireland DAC